SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5189.17M
Enterprise Value 390.97M
Trailing P/E N/A
Forward P/E 1-2.97
PEG Ratio (5 yr expected) 1-0.13
Price/Sales (ttm)15.48
Price/Book (mrq)1.73
Enterprise Value/Revenue 37.44
Enterprise Value/EBITDA 6-2.23

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3-11.72%
S&P500 52-Week Change 3-0.33%
52 Week High 314.48
52 Week Low 35.52
50-Day Moving Average 310.28
200-Day Moving Average 311.50

Share Statistics

Avg Vol (3 month) 359.26k
Avg Vol (10 day) 319.48k
Shares Outstanding 514.37M
Float 10.01M
% Held by Insiders 123.71%
% Held by Institutions 153.59%
Shares Short (Jul 31, 2019) 4415.62k
Short Ratio (Jul 31, 2019) 48.49
Short % of Float (Jul 31, 2019) 43.25%
Short % of Shares Outstanding (Jul 31, 2019) 42.23%
Shares Short (prior month Jun 28, 2019) 4316.16k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-338.41%

Management Effectiveness

Return on Assets (ttm)-26.51%
Return on Equity (ttm)-44.81%

Income Statement

Revenue (ttm)12.22M
Revenue Per Share (ttm)0.70
Quarterly Revenue Growth (yoy)365.70%
Gross Profit (ttm)-29.92M
EBITDA -40.77M
Net Income Avi to Common (ttm)-39.28M
Diluted EPS (ttm)-2.24
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)103.41M
Total Cash Per Share (mrq)5.54
Total Debt (mrq)4.85M
Total Debt/Equity (mrq)4.42
Current Ratio (mrq)13.66
Book Value Per Share (mrq)5.86

Cash Flow Statement

Operating Cash Flow (ttm)-42.02M
Levered Free Cash Flow (ttm)-28.88M